
Pfizer faces setback in trial of weight-loss drug
Pfizer Inc. halted development of its highest-profile experimental drug, an obesity pill aimed at the blockbuster weight-loss market dominated by shots from Novo Nordisk A/S and Eli Lilly & Co., after it was linked to liver damage in a clinical …